presented

Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis

RIDGEFIELD, Conn., July 11, 2007 /PRNewswire/ -- Phase 3 resultsfrom the RE-NOVATE(TM) trial demonstrated that oral dabigatranetexilate once daily, administered for an average of 33 days, wasnon-inferior to enoxaparin, also administered for an average of 33days, in preventing venous thromboembolism (VTE) and all-causemortality after total hip replacement surgery. In this trial, therate o...

Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society

- Co-Injection of rHuPH20 with Humira Estimated to Increase theMaximal Steady State Subcutaneous Bioavailability from 64% to 100%- SAN DIEGO, July 09, 2007 /PRNewswire-FirstCall/ -- HalozymeTherapeutics, Inc. , a biopharmaceutical company developing andcommercializing recombinant human enzymes, today announced thatfinal results of the Enhanze(TM) Technology clinical trialdemonstrating im...

Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology

LUGANO, Switzerland--(BUSINESS WIRE)--Jul 9, 2007 - ZIOPHARMOncology, Inc. (NASDAQ: ZIOP) announces that positive interim datafrom an ongoing phase II trial of ZIO-201 (isophosphoramide mustard- IPM) to treat advanced sarcoma patients was presented at theEuropean Society of Medical Oncology (ESMO) meeting held July 5-8,2007 in Lugano, Switzerland. The abstract entitled, "Phase-I/IIStudy of...

Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Jul 3, 2007 - NymoxPharmaceutical Corporation (NASDAQ: NYMX) today announced thatfurther clinical results from the Company's studies of NX-1207 forbenign prostatic hyperplasia (BPH) will be presented at the NewEngland Section of the American Urological Association Meeting inBoston in September. The paper is authored by leading clinicalresearch inves...

The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece

BRUSSELS, Belgium and KOS, Greece, June 29, 2007 /PRNewswire/ --The European Myeloma Platform (EMP) says updated data forpreviously treated patients on REVLIMID (lenalidomide) plus thesteroid dexamethasone shows median survival of 35 months, nearlythree years. The data are pooled from two large randomizedcontrolled Phase III trials that enrolled more than 700 patientsfrom nearly 100 clin...

ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop

KOS, Greece--(BUSINESS WIRE)--Jun 28, 2007 - ZIOPHARM Oncology,Inc. (NASDAQ: ZIOP), announced today the presentation of twoposters at the XIth Annual International Myeloma Workshop beingheld in Kos, Greece from June 25-28th, 2007. The meeting highlightsimportant advances made in the biology and treatment of multiplemyeloma. ZIOPHARM is presenting darinaparsin (ZIO-101) geneexpression profil...

Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings

HASBROUCK HEIGHTS, NJ (June 21, 2007) Nymox PharmaceuticalCorporation (NASDAQ: NYMX) today announced that detailed resultsfrom the Company’s recently completed studies of NX-1207 forbenign prostatic hyperplasia (BPH) will be presented at a series ofupcoming U.S. urology meetings, beginning in September at the SouthCentral American Urological Association Meeting in ColoradoSprings....

MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions

Data from the PROactive and CHICAGO studies of ACTOS(R)(pioglitazone HCl) will be presented in poster format at the 67thScientific Sessions of the American Diabetes Association inChicago: -- Hospitalizations for serious adverse events in high-risk type 2 diabetes patients treated with pioglitazone for 3...

Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - NymoxPharmaceutical Corporation (NASDAQ: NYMX) today announced thatdetailed results from the Company's recently completed studies ofNX-1207 for benign prostatic hyperplasia (BPH) will be presented ata series of upcoming U.S. urology meetings, beginning in Septemberat the South Central American Urological Association Meeting inColorado...

ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting

MONTREAL, June 19 /CNW/ - ConjuChem Biotechnologies (TSX:CJB)today announced that data relating to its proprietaryPC-DAC(TM):Exendin-4 Albumin Conjugate for the treatment ofType 2 diabetes will be presented at the 67th ScientificSessions of the American Diabetes Association (ADA) to beheld June 22-26, 2007 in Chicago, IL. The ADA's annualScientific Sessions meeting is one of the larges...

New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes

RIDGEFIELD, Conn., June 18, 2007 /PRNewswire/ -- Today, resultsfrom AMADEO*, one of a series of studies comparing two angiotensinreceptor blockers (ARBs) in hypertensive patients with diabeticnephropathy, were presented at the 17th annual European Meeting onHypertension in Milan, Italy. The randomized, double-blind, forced titration, parallel group,multicenter study included 860 hy...

Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo

Demonstrates Positive Effect on Objective and Subjective SleepMeasures MINNEAPOLIS, June 13, 2007 /PRNewswire-FirstCall/ -- Accordingto study results presented today at SLEEP 2007, the 21st annualmeeting of the Associated Professional Sleep Societies (APSS),VEC-162, a balanced melatonin (MT1/MT2) receptor agonist beingdeveloped by Vanda Pharmaceuticals Inc. , demonstrated improvementsin...

Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting

BRANFORD, Conn.--(BUSINESS WIRE)--Jun 13, 2007 - NeurogenCorporation (Nasdaq: NRGN) today announced that data from previousPhase 1 and Phase 2a clinical studies for NG2-73, the Company'slead compound for the treatment of insomnia, were presented in twosessions at the SLEEP 2007 Annual Meeting of the AssociatedProfessional Sleep Societies (APSS) in Minneapolis, Minnesota. TwoPhase 2b clinica...

Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 14, 2007 - CombinatoRx,Incorporated (NASDAQ: CRXX) today announced the presentation ofadditional data related to its immuno-inflammatory productcandidates, CRx-102 and CRx-139, at the European League AgainstRheumatism (EULAR) Annual Congress of Rheumatology meeting, June13-16, 2007 in Barcelona, Spain. In a poster entitled "Inhibition...

Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology

PETACH TIKVA, Israel--(BUSINESS WIRE)--Jun 14, 2007 - Can-FiteBioPharma (TASE:CFBI), a biotechnology company traded on the TelAviv Stock Exchange Exchange, proceeds with the development of itsthird drug CF502; this is in addition to CF101, which is currentlyin clinical trials and CF102, which is in preclinical phases. Thisweekend Can-Fite will present at the EUALR annual congress ofrheumato...

Enbrel Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR

THOUSAND OAKS, Calif. & COLLEGEVILLE, Pa.--(BUSINESS WIRE)--Jun13, 2007 - Amgen (NASDAQ:AMGN) and Wyeth Pharmaceuticals, adivision of Wyeth (NYSE:WYE), today announced the presentation ofadditional data that showed that the safety profile of Enbrel(R)(etanercept) was maintained with long-term use in patients withmoderate-to-severe juvenile rheumatoid arthritis (JRA) whocompleted up to e...

Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia

Data Highlights the Impact of Insomnia on Healthcare System andWorker Productivity SAN DIEGO, June 12, 2007 /PRNewswire-FirstCall/ -- NeurocrineBiosciences, Inc. announced today that results from severalresearch studies on the impact of chronic primary and transientinsomnia were presented this week at the Associated ProfessionalSleep Societies (APSS) Annual Meeting. APSS highlights show t...

Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting

BRANFORD, Conn.--(BUSINESS WIRE)--Jun 11, 2007 - NeurogenCorporation (Nasdaq: NRGN) today announced that data from previousPhase 1 clinical studies for NG2-73, the Company's lead compoundfor the treatment of insomnia, were presented today at the SLEEP2007 Annual Meeting of the Associated Professional Sleep Societies(APSS) in Minneapolis, Minnesota. Two Phase 2b clinical studieswith NG2-73 i...

Clavis Pharma Presented Preliminary Clinical Data on Elacyt at EHA

OSLO, Norway, 11 June 2007 - Clavis Pharma (OSE: CLAVIS)presented an update of data from its ongoing clinical Phase I/IIstudy with ELACYT in hematologic cancers during a poster session atthe Annual Meeting of the European Hematology Association (EHA) inVienna. ELACYT is a novel cytotoxic agent in development for thetreatment of hematologic cancers as well as for solid tumours. Inthis ong...

Data Showing that ReGen's Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia

London, UK, June 11, 2007-ReGen is pleased to announce thata review of scientific and clinical information on Colostrinin, itsnutraceutical product which the Company believes has the potentialto support healthy cognitive function, was presented today at the2007 International Congress on Natural Medicine in SurfersParadise, Queensland, Australia by Dr Marian Kruzel, ReGen's ChiefScientifi...

Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007

HAMBURG, Germany, June 11, 2007 /PRNewswire/ -- NovaCardia, Inc.today presented preliminary results from a pilot Phase 3 trial ofKW-3902, an adenosine A1 receptor antagonist in development for thetreatment of patients with acute congestive heart failure (CHF),that indicate a strong trend toward efficacy for the 30 milligramdose. Patients treated with KW-3902 experienced a higher rate ofi...

Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 6, 2007 - CombinatoRx,Incorporated (NASDAQ: CRXX), today announced that data from itsrandomized, blinded, placebo-controlled phase 2 clinical trials ofCRx-102 in patients with osteoarthritis (OA) and rheumatoidarthritis (RA) will be featured at the European League againstRheumatism (EULAR) Annual Congress of Rheumatology meeting, June13-16, 2007 in Bar...

Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer Study Presented at ASCO

Safety, Efficacy and Markers Demonstrated in Combination Trial ROCKVILLE, Md., June 06, 2007 /PRNewswire-FirstCall/ --EntreMed, Inc. , a clinical-stage pharmaceutical company developingtherapeutics primarily for the treatment of cancer and inflammatorydiseases, announced the presentation of interim data from the Phase1b study with Panzem(R) NCD (2ME2 or 2-methoxyestradiol) incombination w...

Faust Pharmaceuticals' Phase IIa Results for Parkinson's Disease Presented at International Congress of Parkinson's Disease and Movement Disorders

Faust's lead molecule, FP0011, exhibited a differentiatedcombination of therapeutic effects and good tolerance in mid- tolate-stage patients STRASBOURG, France, June 6, 2007 - Faust Pharmaceuticals S.A., aclinical stage product company specializing in the discovery anddevelopment of drugs for diseases of the nervous system, todayannounced that the Phase IIa clinical trial results of its s...

Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting

NEW YORK--(BUSINESS WIRE)--Jun 5, 2007 - ERBITUX (cetuximab), thefirst approved IgG1 monoclonal antibody targeting the epidermalgrowth factor receptor (EGFR) developed and commercialized byImClone Systems Incorporated, was the focus of nine oral and 46poster presentations at the recently concluded 43rd Annual Meetingof the American Society of Clinical Oncology (ASCO). This year's ASCO ERB...

Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal Antibody IMC-A12 Presented at ASCO

NEW YORK--(BUSINESS WIRE)--Jun 5, 2007 - First-in-human results forIMC-A12, a monoclonal antibody developed by ImClone SystemsIncorporated (NASDAQ: IMCL) and targeted to IGF-1R (insulin-likegrowth factor type 1 receptor), were presented at the annualmeeting of the American Society of Clinical Oncology in Chicago.The IGF-IR is expressed on the cell surface of must human cancersand transmits...

MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

2007 American Society of Clinical Oncology (ASCO) AnnualMeeting --Dacogen(R) Activity in Older Patients with AML and inRefractory --Differentiation of the molecular interaction of Aloxi(R)with --Results of a Survival Analysis of Glioblastoma PatientsT...

Cogane Data Presented at ‘11th International Congress of Parkinson’s Disease and Disorders’

GODMANCHESTER, England - (5 June 2007) -Phytopharm plc (LSE: PYM) ("Phytopharm" or the "Company") announcestoday pre-clinical data showing that Cogane(tm) reverses thechanges in the area of the brain involved in Parkinson's disease.This data will be presented by Dr Jonathan Brotchie, aninternationally recognised expert on Parkinson's disease at 'The11th International Congres...

MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - MGI Pharma, Inc.(Nasdaq:MOGN), a biopharmaceutical company focused in oncology andacute care, today provided highlights of data presentations madeduring the 2007 American Society of Clinical Oncology (ASCO) AnnualMeeting. Dacogen (decitabine) for Injection was the subject of fiveposters including the presentation of efficacy data in olderpatients with...

Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study Presented at ASCO

Safety and Single-Agent Activity Support Development of Panzem(R)NCD as a Combination Therapy for Glioblastoma Multiforme ROCKVILLE, Md., June 05, 2007 /PRNewswire-FirstCall/ --EntreMed, Inc. , a clinical-stage pharmaceutical company developingtherapeutics for the treatment of cancer and inflammatory diseases,announces the presentation of results of a single-agent Phase 2study for Panzem(...

Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO

BERKELEY HEIGHTS, NJ – June 4, 2007 – GentaIncorporated (Nasdaq: GNTA) announced the presentation of resultsfrom a Phase 2 clinical trial of its marketed product, Ganite®(gallium nitrate injection), plus rituximab (Rituxan®;Genentech/IDEC) and dexamethasone in patients with relapsed orrefractory non-Hodgkin’s lymphoma (NHL). The data werepresented at the annual mee...

Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting

-- All pre-specified subset analyses of progression-free survivalin the SPARC Phase 3 trial consistently demonstrate a reduction inrelative risk of disease progression for patients receivingsatraplatin. These analyses included prior Taxotere use,geographies, as well as presence or absence of pain. -- The twomajor causes of progression in the SPARC trial - radiologicprogression and pain prog...

Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting

- All pre-specified subset analyses of progression-free survival inthe SPARC Phase 3 trial consistently demonstrate a reduction inrelative risk of disease progression for patients receivingsatraplatin. These analyses included prior Taxotere use,geographies, as well as presence or absence of pain. CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- PharmionCorporation and GPC Biotech AG today...

Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO

BERKELEY HEIGHTS, N.J., June 04, 2007 /PRNewswire-FirstCall/ --Genta Incorporated announced the presentation of results from aPhase 2 clinical trial of its marketed product, Ganite(R) (galliumnitrate injection), plus rituximab (Rituxan(R); Genentech/IDEC) anddexamethasone in patients with relapsed or refractory non-Hodgkin'slymphoma (NHL). The data were presented at the annual meeting of...

Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference

Pre-clinical Data Suggests Angiolix Can Inhibit Breast CancerGrowth By 75% DALLAS and IRVINE, Calif., June 04, 2007 /PRNewswire-FirstCall/-- Access Pharmaceuticals, Inc. (Bulletin Board: ACCP) and SomantaPharmaceuticals, Inc. (Bulletin Board: SMPM) announced today that ascientific abstract outlining new preclinical efficacy data forSomanta's Angiolix has been selected for publication in t...

CYT003-QbG10 to treat allergy to be presented at the Congress of the European Academy of Allergology and Clinical Immunology (EAACI), June 9-13, 2007

Zurich, June 1, 2007-Cytos Biotechnology AG is delighted toinform you about the upcoming scientific presentations of its novelimmunotherapeutic CYT003-QbG10 to treat allergic diseases.Recently, positive clinical results for CYT003-QbG10 were obtainedand will be presented in different sessions at the XXVI Congress ofthe European Academy of Allergology and Clinical Immunology(EAACI), takin...

Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO

CAMBRIDGE, Mass. and GAITHERSBURG, Md., May 31, 2007 (PRIMENEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) andMedImmune, Inc. (Nasdaq:MEDI) today announced that interim clinicaldata on IPI-504 in a Phase I trial in patients withgastrointestinal stromal tumors (GIST) and other soft tissuesarcomas (STS), will be presented at the 2007 Annual Meeting of theAmerican Society of Clini...

Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO Annual Meeting

Diversity of Abstracts Reflects Continued Growth of Eisai'sCommitment to Oncology WOODCLIFF LAKE, N.J., May 31, 2007 /PRNewswire/ -- Eisaiannounced today that several abstracts covering clinical data abouttheir oncology pipeline compounds have been accepted forpresentation at the American Society of Clinical Oncology (ASCO)annual meeting. ASCO takes place in Chicago from June 1-5,2007.</...

OncoGenex and Isis Announce OGX-011 Data to be Presented at ASCO

VANCOUVER and CARLSBAD, CA, May 31, 2007 /PRNewswire-FirstCall/- OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. todayannounced that preliminary data from ongoing clinical studies ofOGX-011 will be presented at the American Society of ClinicalOncology Annual Meeting (ASCO). Presentations will include datafrom a Phase II clinical study of OGX-011 in hormone refractoryprostate c...

Review of Nexavar Data Presented at ASCO 2007- Investor Conference Call on June 4, 2007

Leverkusen, Germany, May 31, 2007- Results from variousclinical studies including a pivotal Phase III trial in patientswith advanced hepatocellular carcinoma, or primary liver cancerwith Nexavar (sorafenib) tablets will be presented at the AnnualMeeting of the American Society of Clinical Oncology (ASCO) inChicago, USA from June 1 - 5, 2007. On this occasion a conference call for i...